Financial Reports Latest Updates Industry Maps Economic Calendar

Syndax Pharmaceuticals Inc (SNDX) Annual Reports

Q: Where can I read Syndax Pharmaceuticals Inc (SNDX) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Syndax Pharmaceuticals Inc is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1395937 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$72.8M	$38.0M	+91.8%
Operating income	$-40.0M	$-69.4M	+42.3%
Net income	$-49.4M	$-71.8M	+31.3%
EPS (diluted)	$-0.55	$-0.83	+33.7%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 72.8 mn Net income -49.4 mn

Show table：Income statement

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	—	0.02	0.31	0.31	0.31	0.31	0.31	0.31	0.31	0.31	0.31	1.19	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	12.4	127	—	—	—	0	—	0	0	0	0	3.50	12.5	7.68	20.0	38.0	45.9	68.7	64.9	72.8
Operating income	-21.3	-4.43	-5.54	-5.86	-4.68	-8.75	-8.63	-15.2	-11.1	-13.2	-13.8	-15.4	-19.5	-19.8	-18.9	-17.8	-19.3	-14.8	-15.4	-13.2	-14.2	-15.1	-16.6	-19.9	-19.9	-27.2	-22.3	-20.0	95.8	-36.9	-37.7	-35.1	-42.0	-46.0	-49.7	-56.4	-77.9	-79.5	-74.2	-89.6	-96.4	-83.8	-69.3	-57.4	-62.5	-34.2	-40.0
Net income	-19.8	-4.91	-6.21	-7.73	-5.26	-10.3	-8.36	-15.0	-10.8	-13.0	-13.6	-15.1	-19.1	-19.4	-18.4	-17.3	-18.8	-14.3	-14.9	-12.8	-14.0	-15.2	-17.1	-20.4	-20.4	-27.7	-22.9	-20.6	96.2	-37.2	-37.6	-35.4	-39.2	-41.1	-44.6	-51.1	-72.5	-72.4	-68.1	-84.1	-94.2	-84.8	-71.8	-60.7	-68.0	-42.7	-49.4

Balance sheet

Quarterly · In mn (USD)

Total assets 704 mn Total liabilities 689 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	—	88.0	136	127	117	109	97.1	134	124	133	119	105	95.8	83.3	97.6	85.8	74.8	62.3	104	192	177	299	279	263	238	448	420	392	358	490	442	409	381	581	454	446	415	603	549	532	530	528	471	675
Total assets	—	—	—	—	89.9	136	128	118	109	97.7	135	124	137	120	105	96.5	83.9	99.4	87.4	76.4	63.5	105	193	179	301	280	263	240	450	422	406	360	497	460	431	399	613	543	477	426	725	641	596	552	530	473	704
Current liabilities	—	—	—	—	4.85	7.04	6.55	9.15	10.4	11.0	11.5	14.2	15.8	16.9	19.3	17.0	16.1	15.7	17.5	18.3	18.4	18.8	12.5	15.2	18.9	24.6	24.3	28.7	20.7	30.6	30.9	20.8	29.1	23.7	30.2	39.2	58.1	50.8	42.5	59.4	104	94.5	113	114	120	86.2	99.7
Total liabilities	—	—	—	—	23.2	22.4	21.6	23.9	24.9	25.1	25.3	27.8	32.9	33.0	35.0	32.2	30.9	30.8	32.1	32.3	31.9	51.6	45.0	47.3	48.4	51.5	48.5	40.5	41.3	47.7	44.5	21.6	29.8	24.3	31.3	40.0	58.7	51.1	42.6	59.4	437	426	439	436	465	431	689
Equity	-153	—	—	—	-252	114	106	93.8	84.1	72.6	109	96.7	104	87.0	70.3	64.3	53.0	68.6	55.3	44.0	31.6	53.5	148	132	252	228	215	199	408	375	362	338	467	436	400	359	554	492	434	366	288	215	157	115	64.6	41.6	15.1

Cash flow

Quarterly · In mn (USD)

Operating -30.3 mn Investing -16.9 mn Financing 253 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-14.4	11.1	-4.00	-5.18	-4.29	-6.40	-6.89	-11.4	-10.4	-12.7	-11.8	-10.2	-12.7	-19.9	-15.2	-18.5	-15.0	-16.8	-12.5	-8.53	-12.7	-15.9	-21.4	-18.3	-15.6	-22.6	-24.0	-24.9	101	-41.9	-40.3	-28.5	-22.9	-39.2	-35.4	-44.6	-41.4	-83.5	-71.6	-62.3	-57.4	-95.2	-87.8	-70.5	-69.5	-50.3	-30.3
Investing	1.89	-19.5	-17.2	-7.41	-17.6	-47.1	-0.62	8.05	21.4	11.1	-36.6	6.92	1.55	12.6	19.3	3.51	16.0	12.8	-18.9	12.4	6.60	-19.1	-78.6	19.3	-64.1	-29.2	21.7	26.6	-60.0	8.18	-50.0	-6.79	-138	19.9	73.9	40.1	-16.3	-99.4	61.8	86.8	-269	94.1	41.9	72.4	81.6	38.4	-16.9
Financing	12.4	7.71	18.7	60.1	-9.18	53.5	-1.23	1.71	0.18	0.12	49.0	1.00	25.6	0.03	0.09	9.46	6.15	28.4	0.01	0.08	0.06	55.0	109	1.77	139	0.96	6.02	1.71	110	0.56	21.7	-13.5	164	2.47	1.32	1.85	258	2.17	0.68	3.10	347	0.93	0.55	6.28	5.92	7.92	253
Cash at period end	10.0	9.28	6.75	54.2	23.2	23.2	14.4	12.8	23.8	22.4	23.0	20.7	35.2	28.0	32.2	26.7	33.8	58.1	26.7	30.6	24.6	44.6	53.6	56.4	115	64.4	68.0	71.4	222	189	120	71.4	74.4	57.5	97.3	94.5	295	115	105	133	154	154	109	117	135	131	336

Profitability

Quarterly · %

Operating margin -55.0% Net margin -67.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	—	—	-32600.0%	-1920.7%	-1534.1%	-2869.8%	-2830.8%	-4996.1%	-3652.8%	-4320.3%	-4538.4%	-5064.3%	-1633.6%	-5211.4%	-5000.3%	-4707.4%	-5087.6%	-3907.9%	-4056.5%	-3469.4%	-3738.2%	-3984.2%	-4382.6%	-5238.3%	-5226.3%	-7167.0%	-5892.9%	-161.9%	75.7%	—	—	—	—	—	—	—	—	—	-2120.5%	-716.6%	-1254.8%	-417.9%	-182.7%	-125.2%	-91.0%	-52.7%	-55.0%
Net margin	—	—	-36552.9%	-2534.8%	-1725.6%	-3386.9%	-2740.3%	-4907.9%	-3545.9%	-4252.8%	-4471.8%	-4946.9%	-1601.3%	-5118.2%	-4851.7%	-4574.7%	-4957.1%	-3773.6%	-3935.6%	-3385.0%	-3684.2%	-4020.1%	-4501.9%	-5392.4%	-5374.5%	-7314.8%	-6044.9%	-166.8%	76.0%	—	—	—	—	—	—	—	—	—	-1944.7%	-673.0%	-1226.2%	-423.3%	-189.3%	-132.4%	-99.0%	-65.8%	-67.8%

Returns & leverage

Quarterly · %

ROE -255.9% ROA -34.0% Debt ratio 97.8%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	-25.9%	-29.8%	-41.5%	—	-50.5%	-48.6%	-55.1%	-64.5%	-84.3%	-80.1%	-92.2%	-94.0%	-88.5%	-104.1%	-112.4%	-132.4%	-93.3%	-58.3%	-75.8%	-51.6%	-60.8%	-50.5%	-55.4%	7.5%	5.1%	0.3%	-5.2%	-34.1%	-37.9%	-42.1%	-50.5%	-41.0%	-51.9%	-63.3%	-81.9%	-75.7%	-93.7%	-113.2%	-129.3%	-161.8%	-189.5%	-255.9%
ROA	—	—	—	—	-26.8%	-21.7%	-24.8%	-33.1%	-44.7%	-40.3%	-39.9%	-43.4%	-49.4%	-61.8%	-60.0%	-67.2%	-66.9%	-62.8%	-67.8%	-70.5%	-76.0%	-55.7%	-42.2%	-52.2%	-40.2%	-44.5%	-40.2%	-43.8%	6.6%	4.4%	0.2%	-4.7%	-31.5%	-34.8%	-38.3%	-46.4%	-37.7%	-48.0%	-58.1%	-72.0%	-47.7%	-56.0%	-62.4%	-63.7%	-45.5%	-43.7%	-34.0%
Debt ratio	—	—	—	—	25.8%	16.4%	16.9%	20.3%	22.8%	25.6%	18.8%	22.3%	24.0%	27.5%	33.2%	33.4%	36.8%	30.9%	36.8%	42.3%	50.3%	49.1%	23.4%	26.4%	16.1%	18.4%	18.4%	16.9%	9.2%	11.3%	10.9%	6.0%	6.0%	5.3%	7.3%	10.0%	9.6%	9.4%	8.9%	13.9%	60.3%	66.4%	73.6%	79.1%	87.8%	91.2%	97.8%

EPS

Quarterly · US$

EPS US$-0.55

Show table：EPS

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-1.84	—	—	—	-1.87	—	-0.44	-0.40	1.84	-0.63	-0.62	-0.58	-0.62	-0.59	-0.64	-0.73	-1.01	-0.85	-0.80	-0.98	-1.09	-0.98	-0.83	-0.70	-0.78	-0.48	-0.55

Revenue & profit

Year-to-date · In mn (USD)

Revenue 138 mn Net income -92.0 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 704 mn Total liabilities 689 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -80.6 mn Investing 21.5 mn Financing 261 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -53.9% Net margin -66.9%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -255.9% ROA -34.0% Debt ratio 97.8%

EPS

Year-to-date · US$

EPS US$-1.03

Revenue & profit

Annual · In mn (USD)

Revenue 173 mn Net income -285 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	—	1.22	2.11	1.52	1.52	1.52	140	—	—	23.7	173
Operating income	-20.5	-43.8	-62.0	-75.9	-57.5	-71.4	26.2	-152	-230	-340	-273
Net income	-24.1	-44.5	-60.8	-74.0	-56.0	-73.2	24.9	-149	-209	-319	-285

Balance sheet

Annual · In mn (USD)

Total assets 530 mn Total liabilities 465 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	88.0	109	133	83.3	62.3	299	448	490	581	603	528
Total assets	89.9	109	137	83.9	63.5	301	450	497	613	725	530
Current liabilities	4.85	10.4	15.8	16.1	18.4	18.9	20.7	29.1	58.1	104	120
Total liabilities	23.2	24.9	32.9	30.9	31.9	48.4	41.3	29.8	58.7	437	465
Equity	-252	84.1	104	53.0	31.6	252	408	467	554	288	64.6

Cash flow

Annual · In mn (USD)

Operating -323 mn Investing 290 mn Financing 13.7 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-2.43	-35.2	-47.4	-68.5	-50.6	-71.3	29.1	-134	-161	-275	-323
Investing	-61.7	-18.3	-17.1	51.4	12.8	-143	-40.9	-186	118	-220	290
Financing	77.3	54.2	75.7	15.7	28.6	304	118	172	264	353	13.7
Cash at period end	23.2	23.8	35.2	33.8	24.6	115	222	74.4	295	154	135

Profitability

Annual · %

Operating margin -158.2% Net margin -165.4%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	-3587.4%	-2939.0%	-5001.7%	-3792.9%	-4708.2%	18.8%	—	—	-1434.4%	-158.2%
Net margin	—	-3645.3%	-2884.3%	-4875.5%	-3694.6%	-4822.5%	17.8%	—	—	-1346.1%	-165.4%

Returns & leverage

Annual · %

ROE -161.8% ROA -45.5% Debt ratio 87.8%

Show table：Returns & leverage

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	—	-64.5%	-94.0%	-132.4%	-51.6%	7.5%	-34.1%	-41.0%	-75.7%	-161.8%
ROA	-26.8%	-44.7%	-49.4%	-66.9%	-76.0%	-40.2%	6.6%	-31.5%	-37.7%	-47.7%	-45.5%
Debt ratio	25.8%	22.8%	24.0%	36.8%	50.3%	16.1%	9.2%	6.0%	9.6%	60.3%	87.8%

EPS

Annual · US$

EPS US$-3.29

Show table：EPS

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	—	-2.45	-2.97	-3.72	-3.29

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Syndax Pharmaceuticals Inc (SNDX) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.